Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 125

Sort by

Sort Order Select

Journal Articles

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Monica S Nair, Sara K Silbert, Kai Rejeski, Karilynn A Wilson, Adam Joseph Lamble, Yannis K. Valtis, Bonnie Yates, Alexa Morales Arana, Roni Shouval, Kevin J. Curran, Rebecca A Gardner, Haneen Shalabi, Colleen Annesley, Jae H. Park, Marion Subklewe, Nirali N Shah

Blood blood.2024025910.

https://doi.org/10.1182/blood.2024025910

Published: 2024

Includes: Supplemental data

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood blood.2024025366.

https://doi.org/10.1182/blood.2024025366

Published: 2024

Includes: Supplemental data

Journal Articles

T cells take aim in AML: targeting IDH2

Marion Subklewe

Blood (2024) 143 (17): 1681–1682.

https://doi.org/10.1182/blood.2024023892

Published: 2024

Journal Articles

Accomplices in Cure: Blinatumomab + Dasatinib Reduces TCR Signaling and Effector Function Stronger Than Ponatinib and Ameliorates T-Cell Exhaustion

Nora Philipp, Anetta Marcinek, Gerulf Hänel, Daniel Nixdorf, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 1511.

https://doi.org/10.1182/blood-2023-179286

Published: 2023

Journal Articles

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Mueller, Wolfgang Andreas Bethge, Javier L. Munoz, Razan Mohty, Veit L. Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe

Blood (2023) 142 (Supplement 1): 359.

https://doi.org/10.1182/blood-2023-180607

Published: 2023

Journal Articles

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

Nicola Goekbuget, Stefan Schwartz, Christoph Faul, Max S. Topp, Marion Subklewe, Andrea Renzelmann, Andrea Stoltefuss, Bernd Hertenstein, Anne Wilke, Simon Raffel, Nadja Jäkel, Vladan Vucinic, Dirk Markus Niemann, Lena Reiser, Hubert Serve, Monika Brüggemann, Andreas Viardot

Blood (2023) 142 (Supplement 1): 964.

https://doi.org/10.1182/blood-2023-180472

Published: 2023

Journal Articles

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 227.

https://doi.org/10.1182/blood-2023-184942

Published: 2023

Journal Articles

Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response

Francesco Corrado, Jan Wulf, Tobias Straub, Daniel Nixdorf, Anetta Marcinek, Nora Philipp, Chang-Feng Chu, Christina Zielinski, Michael von Bergwelt-Baildon, Viktoria Blumenberg, Maryam Kazerani, Marion Subklewe, Veit L. Buecklein

Blood (2023) 142 (Supplement 1): 600.

https://doi.org/10.1182/blood-2023-188970

Published: 2023

Journal Articles

CD33-TIM3 Dual CAR T Cells: Enhancing Specificity While Maintaining Efficacy Against AML

Yingshuai Wang, Wenjie Lu, Lisa Rohrbacher, Heinrich Flaswinkel, Alica Joana Emhardt, Giulia Magno, Sascha Haubner, Sebastian Kobold, Heinrich Leonhardt, Karl-Peter Hopfner, Dirk H Busch, Veit L. Buecklein, Daniel Nixdorf, Marion Subklewe

Blood (2023) 142 (Supplement 1): 3449.

https://doi.org/10.1182/blood-2023-180890

Published: 2023

Journal Articles

The Battle within: AML´s p53 Strategies to Evade T-Cell Attack

Lis Winter, Lea Pawlowsky, Anetta Marcinek, Bettina Brauchle, Amelie Muth, Maryam Kazerani, Agnese Petrera, Roman Kischel, Alica Joana Emhardt, Maja Rothenberg-Thurley, Annika Maria Dufour, Karsten Spiekermann, Michael Andreeff, Naval Daver, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 1411.

https://doi.org/10.1182/blood-2023-173826

Published: 2023

Journal Articles

Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia

Blood (2023) 142 (Supplement 1): 3512.

https://doi.org/10.1182/blood-2023-185097

Published: 2023

Journal Articles

Impact of Sarcopenia and Subsequent Muscle Loss on Post-CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2023-187294

Published: 2023

Journal Articles

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Mueller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Krauss, Arend von Stackelberg, Semjon Willier, Christina Peters, Tobias Feuchtinger

Blood (2023) 142 (Supplement 1): 2135.

https://doi.org/10.1182/blood-2023-190117

Published: 2023

Journal Articles

Two Players, One Goal: BiTE ® Vs CART Targeting FLT3 in AML

Lisa Rohrbacher, Daniel Nixdorf, Helena Stadler, Bettina Brauchle, Florian Märkl, Nora Philipp, Gerulf Hänel, Anetta Marcinek, Maryam Kazerani, Alica Joana Emhardt, Giulia Magno, Rebecca L. Goldstein, Tobias Straub, Sebastian Kobold, Tara L. Chapman-Arvedson, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 3444.

https://doi.org/10.1182/blood-2023-177922

Published: 2023

Journal Articles

Beyond Mitigating Immune-Related Adverse Events: Glucocorticoids Ameliorate Bispecific Antibody-Mediated T-Cell Exhaustion I n Vitro

Amelie Muth, Nora Philipp, Anetta Marcinek, Tobias Straub, Lis Winter, Gerulf Hänel, Daniel Nixdorf, Lisa Rohrbacher, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 5389.

https://doi.org/10.1182/blood-2023-174258

Published: 2023

Journal Articles

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2023-173302

Published: 2023

Journal Articles

Distinct Temporal Dynamic Serum Metabolite Profiles Characterize Treatment Response and Early Toxicity after B-Cell Lymphoma Directed CAR-T-Cell Therapy

David M. Cordas dos Santos, Amar Hadzic, Martin E. Kirmaier, Werner Schmitz, Viktoria Blumenberg, Kai Rejeski, Veit L. Buecklein, Michael von Bergwelt-Baildon, Marion Subklewe, Sebastian Theurich

Blood (2023) 142 (Supplement 1): 2078.

https://doi.org/10.1182/blood-2023-186178

Published: 2023

Journal Articles

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Blood (2023) 142 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2023-186510

Published: 2023

Journal Articles

Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific

Giulia Petra Rappa, Monika Sponheimer, Gerulf Hänel, Anne-Sophie Neumann, Nora Philipp, Koorosh Korfi, Sylvia Herter, Johannes Sam, Franz Schuler, Christian Klein, Marina Bacac, Pablo Umana, Marion Subklewe

Blood (2023) 142 (Supplement 1): 2058.

https://doi.org/10.1182/blood-2023-180785

Published: 2023

Journal Articles

Sting Activation Improves T-Cell Engaging Immunotherapy of Acute Myeloid Leukemia

Andreas Linder, Daniel Nixdorf, Niklas Kuhl, Ignazio Piseddu, TengTeng Xu, Gunnar Kuut, Simon Veth, Thomas Carell, Roman Kischel, Veit Hornung, Marion Subklewe

Blood (2023) 142 (Supplement 1): 2055.

https://doi.org/10.1182/blood-2023-179115

Published: 2023

NARROW

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

T cells take aim in AML: targeting IDH2

Accomplices in Cure: Blinatumomab + Dasatinib Reduces TCR Signaling and Effector Function Stronger Than Ponatinib and Ameliorates T-Cell Exhaustion

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response

CD33-TIM3 Dual CAR T Cells: Enhancing Specificity While Maintaining Efficacy Against AML

The Battle within: AML´s p53 Strategies to Evade T-Cell Attack

Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia

Impact of Sarcopenia and Subsequent Muscle Loss on Post-CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

Two Players, One Goal: BiTE ® Vs CART Targeting FLT3 in AML

Beyond Mitigating Immune-Related Adverse Events: Glucocorticoids Ameliorate Bispecific Antibody-Mediated T-Cell Exhaustion I n Vitro

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Distinct Temporal Dynamic Serum Metabolite Profiles Characterize Treatment Response and Early Toxicity after B-Cell Lymphoma Directed CAR-T-Cell Therapy

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific

Sting Activation Improves T-Cell Engaging Immunotherapy of Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only